Bank of America
IMUC

Bank of America’s ImmunoCellular Therapeutics, Ltd. IMUC Stock Holding History

Bank of America’s Portfolio IMUC Stock Details IMUC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q4 		– Sell
-16
Closed – – 7561
2017
Q3 		$0 Buy
+16
New +$8 ﹤0.01% 7574
2017
Q2 		– Sell
-129
Closed – – 7461
2017
Q1 		$0 Buy
+129
New +$337 ﹤0.01% 7595
2016
Q4 		– Sell
-69
Closed – – 7727
2016
Q3 		$0 Buy
69
+42
+156% +$270 ﹤0.01% 7718
2016
Q2 		$0 Sell
27
-4
-13% -$41 ﹤0.01% 7773
2016
Q1 		$0 Buy
+31
New +$349 ﹤0.01% 7789
2015
Q4 		– Sell
-4
Closed – – 7769
2015
Q3 		$0 Buy
+4
New +$73 ﹤0.01% 7803
2014
Q4 		– Sell
-100
Closed -$4K – 8451
2014
Q3 		$4K Hold
100
– – ﹤0.01% 7662
2014
Q2 		$4K Buy
+100
New +$4.83K ﹤0.01% 7737
2014
Q1 		– Sell
-12
Closed – – 8679
2013
Q4 		$0 Sell
12
-63
-84% -$5.97K ﹤0.01% 8661
2013
Q3 		$8K Sell
75
-2,235
-97% -$245K ﹤0.01% 7270
2013
Q2 		$179K Buy
+2,310
New +$221K ﹤0.01% 5728

Other funds holding IMUC

Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.88B AUM 32.38% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
APA
American Portfolios Advisors Holbrook, New York $2.36B AUM 14.59% 1-Year Est. Return
RE
RBC Europe London, United Kingdom $2.08B AUM 12.2% 1-Year Est. Return

Bank of America's IMUC Position: Q4 2017 in Review

Bank of America sold out of ImmunoCellular Therapeutics, Ltd. (IMUC) in Q4 2017, closing a stake of 16 shares.

Bank of America first reported a position in IMUC in Q2 2013 and held it in 11 quarters. The position peaked at $179K in Q2 2013. 17 funds tracked by Wall St. Rank hold IMUC as of Q4 2017.

  • Bank of America reported no remaining ImmunoCellular Therapeutics, Ltd. position as of Q4 2017 after selling out during the quarter.
  • Bank of America sold 16 ImmunoCellular Therapeutics, Ltd. shares in Q4 2017.
  • Bank of America first reported a position in ImmunoCellular Therapeutics, Ltd. in Q2 2013 and held it in 11 quarters.
  • Bank of America's ImmunoCellular Therapeutics, Ltd. position peaked at $179K in Q2 2013.
  • 17 funds tracked by Wall St. Rank held ImmunoCellular Therapeutics, Ltd. as of Q4 2017.

Based on Bank of America's 13F filing for Q4 2017, filed 14 Feb 2018.